Hacker News Reader

Maybe that dog lifespan prolonging startup should pitch in. Kinda like how tech startups don't pitch in to fund the open source projects they rely on

This isn't like that at all - that startup (Loyal) is running their own clinical trial, not relying on the aging project.

Do they not directly benefit from those data?

I wonder if that is part of the story here - seems like that company has come along and shown it’s possible to bring a solution to market faster.